Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Polyneuropathy, Inflammatory Demyelinating, Chronic

Interventions

DRUG: Riliprubart Prefilled Pen (PFP)

Sponsor

Sanofi